ClinicalTrials.gg
RecruitingNCT07948772INSPIRE ATUpdated Nov 19, 2026

A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators

An observational study in Ataxia Telangiectasia, sponsored by Insmed Incorporated. Recruiting at 5 sites in 2 countries. Open to participants aged 1 Year to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Insmed Incorporated · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
69
Ages
1 Year to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Ataxia Telangiectasia with a site in United States — 3 open to participants now, 5 under way, 1 of them phase 3. Ataxia Telangiectasia · United States.

Started
2026
with 1 other
Observational
4 of 17
2 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Insmed Incorporated

Among the 17 studies in Ataxia Telangiectasia with a site in United States, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 17th registered.

Ataxia Telangiectasia

43 studies on the registry are indexed under Ataxia Telangiectasia; 8 are open to participants now.

Browse Ataxia Telangiectasia studies →

Open to participants now

3 of the 17 studies in Ataxia Telangiectasia with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Ataxia Telangiectasia studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 10 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ataxia Telangiectasia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.

03

Conditions studied

  • Ataxia Telangiectasia

Browse trials for

Keywords

  • Ataxia Telangiectasia (AT or A-T)
04

Who can participate

Ages eligible
1 Year to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
  • If three years to 10 years (\<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver form.

Inclusion Criteria for the Healthy Comparator Cohort:

  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.

Exclusion criteria

Exclusion Criteria for the AT Cohort:

  • Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in trials, expanded access programs, or as a licensed drug are eligible.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.

Exclusion Criteria for the Healthy Comparator Cohort:

  • Diagnosis of any form of AT.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
69 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • AT Cohort

    Participants with confirmed AT at screening visit will be enrolled and followed for 24 months.

  • Healthy Comparator Cohort

    Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months.

06

What researchers measure

Primary outcomes

  1. AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score

    Time frame: Baseline up to Month 24

  2. AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score

    Time frame: Baseline up to Month 24

Secondary outcomes

  1. Change From Baseline in Height

    Time frame: Baseline up to Month 24

  2. Change From Baseline in Weight

    Time frame: Baseline up to Month 24

  3. Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)

    Time frame: Up to Month 24

  4. AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory

    Time frame: Baseline up to Month 24

  5. Change From Baseline in Motor Activity Assessed by Wearable Device

    A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity.

    Time frame: Baseline up to Month 24

  6. Change From Baseline in Arm Function Assessed by Hevelius Test

    Time frame: Baseline up to Month 24

07

Study locations

4 of 5 sites recruiting
  • USA004
    Los Angeles, California 90095, United States
    Not yet recruiting
  • USA002
    Baltimore, Maryland 21287-0005, United States
    Recruiting
  • USA001
    Boston, Massachusetts 02114, United States
    Recruiting
  • USA003
    Houston, Texas 77030-3008, United States
    Recruiting
  • GBR001
    Nottingham, NG7 2UH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 19, 2026
StartActual
Jun 30, 2026
Primary completionEst.
May 30, 2029
CompletionEst.
May 30, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948772
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jun 30, 2026
Primary completion
May 30, 2029 (estimated)
Completion
May 30, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Insmed Medical Information
Contact
medicalinformation@insmed.com
1-844-446-7633
Study Director
study director · Insmed Incorporated

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion